Venus Protocol — Why a Women’s-Specific Peptide Stack?
Venus Protocol — Why a Women’s-Specific Research Stack?
Women’s biology · Female-specific compound selection · No androgens · Supplied by QSC
⚠️ Research Use Only.
The Problem: Most Peptide Stacks Are Built for Men
The majority of research peptide protocols are optimised for male biology: heavy androgenic compounds (testosterone, Anavar), high-dose GH axis agents (HGH, IGF-1 LR3), and compounds like Melanotan II that target male-pattern appearance goals. For women’s health research, this leaves significant gaps — and introduces unnecessary androgenic and virilisation risks that are irrelevant to female biology.
The Venus Protocol Solution: 6 Female-Relevant Pathways
1. Metabolic — Retatrutide (not Semaglutide or Tirzepatide)
Retatrutide’s triple GLP-1/GIP/GCGR agonism provides the most potent metabolic research compound available without any androgenic properties. Phase 2 data showing 15–24% weight reduction applies to mixed-sex cohorts. The GCGR fat-oxidation pathway is equally active in female subjects.
2. Skin, Collagen & Hair — GHK-Cu + L-Glutathione
GHK-Cu addresses the structural dimension of skin ageing: collagen synthesis, elastin production, ECM remodeling. L-Glutathione addresses the tone dimension: tyrosinase inhibition → pheomelanin shift → skin brightening. Together these cover the full spectrum of non-surgical skin quality research with compounds that have extensive published data in female cohorts.
3. Cellular Longevity — NAD+ + Epithalon (unique to Venus)
Epithalon is the distinguishing anti-aging compound from the Clavicular Ascension Stack. Telomere attrition is sex-influenced: post-menopausal women show accelerated telomere shortening, and telomere length correlates with biological age more strongly in women than men in multiple cohort studies. Epithalon’s telomerase activation mechanism is therefore proportionally more relevant to women’s longevity research. Paired with NAD+’s mitochondrial function support for dual-mechanism coverage.
4. Gut Health — BPC-157 (female-relevant prevalence data)
Irritable bowel syndrome (IBS) affects 1.5–3× more women than men across multiple epidemiological studies. BPC-157’s gut barrier repair, motility modulation, and anti-inflammatory research is therefore not merely generally relevant — it addresses a disproportionately female health burden. The compound’s oral stability in gastric acid adds research versatility.
GH secretagogues that elevate cortisol (GHRP-6) or prolactin (GHRP-2, Hexarelin) are particularly problematic for women’s health research where these hormonal disruptions have downstream menstrual and metabolic consequences. Ipamorelin — with zero cortisol and zero prolactin effects — is the only GH secretagogue appropriate for the Venus Protocol’s hormonal neutrality requirement.
6. Sexual Wellness — PT-141 (women-specific clinical validation)
Hypoactive sexual desire disorder (HSDD) is predominantly studied in women — it is the most common female sexual dysfunction. PT-141/Bremelanotide has the rare distinction of being both the most clinically studied peptide for female sexual desire and the only FDA-acknowledged compound specifically for HSDD in premenopausal women. No androgenic effects, no hormonal manipulation.
Compounds Shared with Clavicular Ascension Stack
Retatrutide · GHK-Cu · NAD+ · L-Glutathione · BPC-157 · TB-500 · CJC-1295 No DAC — 7 of 10 Venus Protocol compounds are also in the men’s Ascension Stack, confirming their cross-sex biological relevance.
Compounds Unique to Venus Protocol
Compound
Why Female-Specific
PT-141
FDA-acknowledged for HSDD in women; RECONNECT programme (1,200+ women); no androgenic effects
Most peptide research stacks are built around androgens (testosterone, Anavar), heavy GH axis compounds (high-dose HGH, IGF-1 LR3), and melanocortin compounds (Melanotan II) that are specifically relevant to male body optimisation research. A women’s-specific stack prioritises compounds with clinical relevance to female biology: hormonal neutrality, skin and collagen, gut health, telomere/longevity, and sexual desire — without virilisation risk.
Is PT-141 safe for women to research?
PT-141 (Bremelanotide) has the most extensive clinical validation of any compound in the Venus Protocol, having been studied in the Phase 3 RECONNECT programme involving 1,200+ premenopausal women. As an FDA-acknowledged compound (Vyleesi), it has undergone rigorous regulatory evaluation. QSC supplies PT-141 for in vitro research use only.
How does the Venus Protocol compare to the Clavicular Ascension Stack?
The Clavicular Ascension Stack (men’s) contains 12 compounds including Testosterone Cypionate, Melanotan II, HGH, IGF-1 LR3, and Anavar. The Venus Protocol replaces androgenic compounds with: PT-141 (sexual wellness without androgens), Epithalon (telomere longevity), and Ipamorelin (clean GH secretagogue). Shared compounds: Retatrutide, GHK-Cu, NAD+, L-Glutathione, BPC-157, TB-500, CJC-1295 No DAC.
